IPASA member companies are at the forefront of developing innovative medicines, improving treatment outcomes, and extending the lives of patients with previously untreatable conditions. Medical breakthroughs have significantly reduced mortality rates for HIV/AIDS and TB in South Africa, with ongoing research promising even more effective treatments.

Advances in chronic leukaemia treatment have led to increased survival rates, showcasing the transformative power of pharmaceutical innovation.

The rising prevalence of non-communicable diseases (NCDs) in South Africa underscores the importance of ongoing research, with over 4,100 new medicines in the pipeline to address conditions like heart disease, stroke, and cancer.

IPASA member companies are committed to enhancing access to quality medicines, exemplified by initiatives like Novartis Access, which offers affordable treatments for chronic diseases.

The focus on prevention, as seen in MSD's efforts to eradicate cervical cancer, highlights the industry's dedication to addressing pressing health challenges.

Pharmaceutical companies' investment in research and development not only drives medical innovation but also contributes to economic growth in South Africa, positioning the country as a regional hub for healthcare solutions.

This summary highlights the significant impact of pharmaceutical innovation on healthcare outcomes and economic development in South Africa.